They are the biotech equivalent of the “missing girls” in countries with a skewed gender ratio: 40 to 50 companies that would have been spun out of research at MIT labs headed by women were it not for …
That’s the multibillion-dollar question: Why don’t women biologists found biotech companies at the same rate as men? For the last year, three prominent Massachusetts Institute of Technology scientists have been collecting statistics, questioning venture capital partners, and meeting with leaders in academia, science, and business to find answers.
Now, data in hand, the trio’s newly formed Boston Biotech Working Group has taken the first steps to remedy the gender imbalance in biotech, they announced on Wednesday — a pledge signed by five venture firms, including Polaris Partners and F-Prime Capital, “to do all in our power to ensure the boards of directors for companies where we hold positions of power are 25% female by the end of 2022.” (Women now hold 14% of board seats.)
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect